依林扎坦与他类非激素疗法治疗中重度绝经相关血管舒缩症状的网络荟萃分析
该研究对Medline、Embase和Cochrane数据库截至2025年10月的随机对照试验进行系统综述与贝叶斯网络荟萃分析,纳入17项RCT,比较依林扎坦与其他非激素药物在中重度绝经相关血管舒缩症状中的疗效。结果显示依林扎坦在降低每日VMS频率、减少夜间觉醒及改善睡眠障碍方面优于或相当于部分对照药物。
要点
- 依林扎坦120 mg在降低每日VMS频率方面优于帕罗西汀、去甲文拉法辛和加巴喷丁。
- 依林扎坦在减少夜间觉醒和改善睡眠障碍方面优于帕罗西汀及所有去甲文拉法辛方案。
- 依林扎坦对MENQoL的改善与其他治疗相比无显著差异。
核心结论
- 在该间接比较中,依林扎坦在降低VMS频率和严重程度以及改善睡眠障碍方面优于或相当于其他NKT或非激素疗法。
- 结果支持依林扎坦在中重度绝经相关VMS管理中的作用。
研究设计与样本
- 系统综述检索Medline、Embase和Cochrane数据库,纳入截至2025年10月发表的随机对照试验。
- 采用贝叶斯网络荟萃分析比较各治疗,效应量以均数差或比值比及其95%可信区间表示。
- 共纳入17项RCT,其中3项评估依林扎坦120 mg。
主要发现
- 依林扎坦显著降低每日VMS频率,对比帕罗西汀的均数差为−2.11(95%CI:−3.31至−0.92)。
- 依林扎坦对比去甲文拉法辛降低VMS频率的均数差范围为−2.77至−1.72,对比加巴喷丁为−2.22至−2.31。
- VMS频率降低≥50%的患者比例:依林扎坦优于去甲文拉法辛100 mg(OR:1.52,95%CI:1.03至2.24)和帕罗西汀(OR:2.20,95%CI:1.49至3.28)。
- 依林扎坦显著降低VMS严重程度,对比去甲文拉法辛50 mg的均数差为−0.37(95%CI:−0.56至−0.17)。
- 依林扎坦减少夜间觉醒显著优于帕罗西汀(均数差:−0.82,95%CI:−1.26至−0.39)及所有去甲文拉法辛方案。
关键数值与推荐
- 纳入对象为未经医疗干预诱发的、中重度VMS女性,且报告第12周VMS频率、严重程度、睡眠障碍及生活质量结果的RCT。
- 对照药物包括帕罗西汀7.5 mg、加巴喷丁1200–1800 mg、非唑奈坦45 mg和去甲文拉法辛50–200 mg。
- 依林扎坦对比非唑奈坦在PROMIS SD-SF-8b睡眠障碍评分的均数差为−2.67(95%CI:−3.92至−1.42)。
临床怎么用
- 对于中重度绝经相关VMS患者,可考虑依林扎坦作为非激素药物治疗选择之一。
- 在关注夜间觉醒和睡眠障碍改善时,依林扎坦可能优于帕罗西汀和去甲文拉法辛。
局限性
- 该研究为网络荟萃分析,结果来自间接比较。
- 研究仅纳入报告第12周结果的RCT,未评估更长期疗效。
- MENQoL变化在各治疗间无显著差异,生活质量获益证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Elinzanetant, a novel, dual neurokinin-targeted therapy, has been approved in various geographies for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non-hormonal pharmaceutical treatments (nHT) in alleviating VMS. Search Strategy A systematic literature review of Medline, Embase, and Cochrane databases identified randomised controlled trials (RCTs) published up to October 2025. Selection Criteria RCTs of nHT in women with moderate-to-severe VMS not induced by medical treatment, reporting week 12 results for VMS frequency and severity, sleep disturbances, and quality of life. Data Collection and Analysis Treatments were compared using a Bayesian network meta-analysis to obtain mean differences (MD) or odds ratios (OR) with 95% credible intervals. Main Results Of 17 included RCTs, three assessed elinzanetant 120 mg, two paroxetine 7.5 mg (PRX), four gabapentin 1200–1800 mg (GABA), three fezolinetant 45 mg (FEZO), and five desvenlafaxine 50–200 mg (DVS). Elinzanetant significantly reduced daily VMS frequency versus PRX (MD: −2.11 [−3.31, −0.92]), DVS (MD: −2.77 to −1.72), and GABA (MD: −2.22 to −2.31). The proportion of patients with ≥ 50% reduction in VMS frequency was significantly greater with elinzanetant than DVS 100 mg (OR:1.52 [1.03, 2.24]) and PRX (OR:2.20 [1.49, 3.28]), and comparable to DVS 150 mg and FEZO. Elinzanetant significantly reduced VMS severity versus DVS 50 mg (MD: −0.37 [−0.56, −0.17]) and was comparable with other assessed treatments. Elinzanetant reduced nighttime awakenings significantly more effectively than PRX (MD: −0.82 [−1.26, −0.39]) and all DVS regimens. Elinzanetant significantly improved sleep disturbance (PROMIS SD-SF-8b) score versus FEZO (MD: −2.67 [−3.92, −1.42]). Change in MENQoL did not differ significantly. Conclusions In this indirect comparison, elinzanetant showed superior or comparable efficacy to NKT or nHT in reducing the frequency and severity of VMS, along with improving sleep disturbances, supporting its role in VMS management.
引用
- BJOG:Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。